Tecentriq 1 200 mg concentrate for solution for infusion clinical trials
5 indexed studies · 4 currently recruiting
- RecruitingTherapeutic exploratory (Phase II)
Phase 2 study of neoadjuvant immune checkpoint inhibitors in urothelial cancer (ABACUS-2)
This clinical trial is testing an immunotherapy drug called atezolizumab (Tecentriq) for people with bladder or upper urinary tract cancer. Researchers want to see if giving this drug before surgery helps shrink or remove cancer cells and prevents the cancer from returning.
For: Tumours of the urothelial tract requiring surgery (T1 high grade-T4a of the bladder, rare histological subtypes) and upper urinary tract (high grade or high risk)Spain · France - RecruitingTherapeutic exploratory (Phase II)
A phase II trial of Atezolizumab plus induction chemotherapy (CT) plus chemo-radiotherapy and Atezolizumab maintenance therapy in non-resectable stage IIIA-IIIB-IIIC non-small cell lung cancer (NSCLC) patients (APOLO)
This study is testing a new way to treat certain advanced non-small cell lung cancer. It combines a drug called Tecentriq with standard chemotherapy and radiotherapy to see if it can stop the cancer from growing for longer.
For: Non-small cell lung cancer (NSCLC)Spain - RecruitingTherapeutic exploratory (Phase II)
Randomized Phase II Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab in Locally Advanced Cervical Cancer (AtezoLACC)
This study is testing a new medicine, Tecentriq, for women with locally advanced cervical cancer. We want to see if it helps patients live longer without their cancer getting worse, compared to standard treatments.
For: Locally advanced cervical cancerFrance - RecruitingPhase I and Phase II (Integrated)- Other
Programmed death ligand 1 (PD-L1) PET imaging in patients with (Diffuse) Large B-cell Lymphoma who are treated with CD19-directed CAR T-cell therapy: a pilot study
This study looks at a special scan before CAR T-cell therapy for lymphoma. It uses a tracer to see how certain proteins in lymphoma cells react. The aim is to understand how this scan can predict treatment success and help tell the difference between active lymphoma and normal swelling.
For: (Diffuse) Large B-cell LymphomaNetherlands - AuthorisedTherapeutic confirmatory (Phase III)
ALBAN : An open label, randomized, phase III trial, evaluating efficacy of Atezolizumab in addition to one year BCG (Bacillus CaLmette-Guerin) bladder instillation in BCG-naive patients with high-risk non-muscle invasive Bladder cANcer
This study looks at a new drug, Tecentriq, combined with standard BCG treatment for high-risk, early bladder cancer that hasn't spread to the muscle. It wants to see if this combination can stop the cancer from coming back or getting worse.
For: High-risk non-muscle invasive bladder cancer (NMIBC) after transurethral resection of the bladder (TURBT) and pathological assessment.Spain · France · Belgium